158 related articles for article (PubMed ID: 38443220)
21. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
24. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
27. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
30. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
Myers GD; Verneris MR; Goy A; Maziarz RT
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33846220
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
32. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
33. CAR T-cell therapy for B-cell lymphoma.
Denlinger N; Bond D; Jaglowski S
Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754
[TBL] [Abstract][Full Text] [Related]
34. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T cell: A cancer immunotherapy.
Singh S; Khasbage S; Kaur RJ; Sidhu JK; Bhandari B
Indian J Pharmacol; 2022; 54(3):226-233. PubMed ID: 35848695
[TBL] [Abstract][Full Text] [Related]
36. Lisocabtagene Maraleucel for the treatment of B-cell lymphoma.
Iragavarapu C; Hildebrandt G
Expert Opin Biol Ther; 2021 Sep; 21(9):1151-1156. PubMed ID: 34030548
[No Abstract] [Full Text] [Related]
37. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
38. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
Dudley CV; Baer B; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
[TBL] [Abstract][Full Text] [Related]
39. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
Frigault MJ; Dietrich J; Martinez-Lage M; Leick M; Choi BD; DeFilipp Z; Chen YB; Abramson J; Crombie J; Armand P; Nayak L; Panzini C; Riley LS; Gallagher K; Maus MV
Blood; 2019 Sep; 134(11):860-866. PubMed ID: 31320380
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]